Stock Analysis on Net
Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Allergan Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Allergan Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011 Dec 31, 2010 Sep 30, 2010 Jun 30, 2010 Mar 31, 2010
Net earnings (loss)
Depreciation and amortization
Amortization of original issue discount and debt issuance costs
Amortization of net realized gain on interest rate swap
Deferred income tax provision (benefit)
Acquired in-process research and development technology
(Gain) loss on disposal and impairment of assets
Unrealized (gain) loss on derivative instruments
Expense of share-based compensation plans
Loss on sale of discontinued operations
Legal settlement
Impairment of intangible assets and related costs
(Income) expense from changes in fair value of contingent consideration
Provision for losses on trade receivables in Venezuela
Restructuring charges
(Gain) loss on investments, net
Pension and other post-retirement benefit plans settlements and curtailments
Non-cash items included in net earnings (loss)
Trade receivables
Inventories
Other current assets
Other non-current assets
Accounts payable
Accrued expenses
Income taxes
Other liabilities
Changes in operating assets and liabilities
Net cash provided by operating activities
Purchases of short-term investments
Purchase of non-marketable equity investment
Acquisitions, net of cash acquired
Additions to property, plant and equipment
Additions to capitalized software
Additions to intangible assets
Contractual purchase price adjustment to prior acquisition
Proceeds from maturities of short-term investments
Proceeds from sale of business
Proceeds from sale of equity investments
Proceeds from sale of property, plant and equipment
Net cash (used in) provided by investing activities
Repayments of convertible borrowings
Dividends to stockholders
Payments to acquire treasury stock
Purchase of noncontrolling interest in a subsidiary
Payments of contingent consideration
Net borrowings (repayments) of notes payable
Sale of stock to employees
Excess tax benefits from share-based compensation
Debt issuance costs
Proceeds from issuance of senior notes, net of discount
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash and equivalents
Net increase (decrease) in cash and equivalents

Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Allergan Inc. net cash provided by operating activities increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Allergan Inc. net cash (used in) provided by investing activities decreased from Q2 2014 to Q3 2014 but then slightly increased from Q3 2014 to Q4 2014.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Allergan Inc. net cash provided by (used in) financing activities increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.